Mexrenone

Mexrenone

Clinical data
Other names	ZK-32055; SC-25152; 7α-(Methoxycarbonyl)canrenone; 17β-Hydroxy-3-oxo-17α-pregn-4-ene-7α,21-dicarboxylic acid γ-lactone methyl ester
Identifiers
IUPAC name methyl (7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-carboxylate
CAS Number	41020-65-9
PubChem CID	3082529
ChemSpider	10257997
UNII	16FTD41OAV
CompTox Dashboard (EPA)	DTXSID101045761
Chemical and physical data
Formula	C24H32O5
Molar mass	400.515 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC(=O)[C@@H]4C\C1=C\C(=O)CC[C@]1(C)[C@H]5CC[C@@]3(C)[C@@H](CC[C@]23CCC(=O)O2)[C@H]45
InChI InChI=1S/C24H32O5/c1-22-8-4-15(25)12-14(22)13-16(21(27)28-3)20-17(22)5-9-23(2)18(20)6-10-24(23)11-7-19(26)29-24/h12,16-18,20H,4-11,13H2,1-3H3/t16-,17+,18+,20-,22+,23+,24-/m1/s1 Key:ADZYJDJNIBFOQE-RGKMBJPFSA-N

Mexrenone (code names ZK-32055, SC-25152) is a steroidal antimineralocorticoid of the spirolactone group related to spironolactone that was never marketed. ^{[1] [2]} It is the lactonic form of mexrenoic acid (mexrenoate), and mexrenoate potassium (SC-26714), the potassium salt of mexrenoic acid, also exists. ^[3] In addition to the mineralocorticoid receptor, mexrenone also binds to the glucocorticoid, androgen, and progesterone receptors. ^[4] Relative to spironolactone, it has markedly reduced antiandrogen activity (approximately one-tenth of the antimineralocorticoid dosage equivalent antiandrogen activity of spironolactone). ^[2] Eplerenone is the 9-11α-epoxy analogue of mexrenone. ^[5]

See also

• Canrenone
• Mexrenoate potassium
• Mexrenoic acid
• Potassium canrenoate
• Prorenone

References

1. Cutler GB, Pita JC, Rifka SM, Menard RH, Sauer MA, Loriaux DL (July 1978). "SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate". The Journal of Clinical Endocrinology and Metabolism. 47 (1): 171–175. doi:10.1210/jcem-47-1-171. PMID   263288.
2. Cutler GB, Sauer MA, Loriaux DL (April 1979). "SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone". The Journal of Pharmacology and Experimental Therapeutics. 209 (1): 144–146. PMID   430374.
3. Hofmann LM, Weier RM, Suleymanov OD, Pedrera HA (June 1977). "Mexrenoate potassium: a steroidal aldosterone antagonist and antihypertensive". The Journal of Pharmacology and Experimental Therapeutics. 201 (3): 762–768. PMID   864608.
4. Szasz G, Budvari-Barany Z (19 December 1990). Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. 87–. ISBN   978-0-8493-4724-5.
5. Ménard J (March 2004). "The 45-year story of the development of an anti-aldosterone more specific than spironolactone". Molecular and Cellular Endocrinology. 217 (1–2): 45–52. doi:10.1016/j.mce.2003.10.008. PMID   15134800. S2CID   19701784.